Close Menu

NEW YORK (GenomeWeb) – NantHealth's revenues fell 6 percent year over year during the second quarter, the company reported after the close of the market on Thursday.

For the three months ended June 30, total revenues declined to $22 million compared to $23.5 million in the same period a year earlier, which included $4 million from a since-ended large implementation in its connected devices business segment, according to NantHealth.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: analysis of link between somatic copy number and telomere length, sequencing study of individuals with gallbladder S. Typhi colonization, and more.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.